Skip to main content
. 2018 May 22;9(6):595. doi: 10.1038/s41419-018-0506-0

Fig. 3. Fer-1 pre-treatment maintains sGSIS in human islets treated with erastin.

Fig. 3

Human islets were pre-treated ±1 μM Fer-1 or ±100 μM DFO for 24 h and subsequently challenged ±50 μM erastin for an additional 24 h. Subsequent to culture, islets were collected and assessed for sGSIS. Cell-free supernatants were assessed for insulin secretion via ELISA and expressed as stimulation index (insulin secreted in response to 16.7 mM glucose vs. insulin secreted in response to 2.8 mM glucose). Data represented as mean ± SEM, triplicate samples from at least three human pancreata. **p < 0.01 (one-way ANOVA, followed by Tukey’s multiple comparison test)